Last reviewed · How we verify
TSR-022
At a glance
| Generic name | TSR-022 |
|---|---|
| Sponsor | Tesaro, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dostarlimab and Cobolimab in Advanced Cervical Cancer (PHASE2)
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (PHASE1)
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (PHASE1)
- Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma (PHASE2)
- TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TSR-022 CI brief — competitive landscape report
- TSR-022 updates RSS · CI watch RSS
- Tesaro, Inc. portfolio CI